Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Lipoprotein-associated phospholipase a2 antibody compositions and methods of use

Inactive Publication Date: 2014-09-18
DIAZYME LAB INC
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent is about an isolated antibody that can attach to a protein called Lp-PLA2, which is associated with a disease called atherosclerosis. The antibody was obtained by culturing cells and can be produced in bacteria or mammalian cells. It can be used to detect or diagnose atherosclerosis by binding to Lp-PLA2 in a sample taken from a patient. The patent also covers methods for making the antibody and compositions containing it for use in diagnosis and treatment of atherosclerosis.

Problems solved by technology

Stroke is a leading cause of death and disability in the world.
These attacks leave a large number of survivors with disabilities.
Peripheral vascular disease (PVD) is a nearly pandemic condition that has the potential to cause loss of limb, or even loss of life.
While tPA or other thrombolytics can reduce disability from a heart attack or stroke, there is also a higher risk of bleeding.
When this occurred, there was a 45 percent fatality rate.
Stroke symptoms alone are insufficient to definitely diagnose stroke and, in patients with a stroke mimic, tPA use results only in potential adverse effects without any possibility of benefit.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Production and Isolation of Monoclonal Antibody Producing Hybridomas

[0244]The following MAb / hybridomas of the present invention are described below:

[0245]LpPLA2.A7.1, LpPLA2.A8.2, LpPLA2.A201.1, LpPLA2.A202.1, LpPLA2.A203.1, LpPLA2.B5.2, LpPLA2.B6, LpPLA2.B17.1, LpPLA2.B17.2, LpPLA2.B26, LpPLA2.B31, LpPLA2.B38.2, LpPLA2.B40, LpPLA2.B44, LpPLA2.B48, LpPLA2.B69, LpPLA2.B71, LpPLA2.B78, LpPLA2.B81, LpPLA2.B82, LpPLA2.B84, LpPLA2.B94, LpPLA2.B98, LpPLA2.B130, LpPLA2.B132, LpPLA2.B142, LpPLA2.B144.1, LpPLA2.B144.2, LpPLA2.B149, LpPLA2.B154, LpPLA2.B155, LpPLA2.B159.3, LpPLA2.B160, LpPLA2.B179, LpPLA2.B194, LpPLA2.B195, LpPLA2.B200.1, LpPLA2.B200.2, LpPLA2.B201.1, LpPLA2.B206, LpPLA2.B213, LpPLA2.B224, LpPLA2.B225, LpPLA2.B228, LpPLA2.B229.1, LpPLA2.B235, LpPLA2.B236, LpPLA2.B238, LpPLA2.B241, LpPLA2.B248, LpPLA2.B251, LpPLA2.B266, LpPLA2.B280, LpPLA2.B281, LpPLA2.B500.6, LpPLA2.B501.5, LpPLA2.C1, LpPLA2.C2, LpPLA2.C3, LpPLA2.C4, LpPLA2.C5, LpPLA2.C6, LpPLA2.C7, LpPLA2.C8, LpPLA2.C9, LpPL...

example 2

Characterization of Antibodies

Pairing of Lp-PLA2 Antibodies

[0257]To evaluate and characterize Lp-PLA2 antibodies of the present invention a luminex pairing assay was performed as set forth in Miller et al., Journal of Immuno Methods 365 (2011) 118-125, the content of which is hereby incorporated by reference in its entirety. Anti-Lp-PLA2 antibodies 2C10 and 4B4 (diaDexus, South San Francisco, Calif.) were used as reference antibodies. The pairing assay identified antibodies which bound Lp-PLA2 antigen and if antibodies bound unique epitopes or competed for binding to epitopes on Lp-PLA2.

[0258]Raw data was sorted as set forth in Miller et al and the pattern of reactivities demonstrated that Lp-PLA2 antibodies group into several ‘bins’.

[0259]Bin 1 comprises B38, and B229;

[0260]Bin 2 comprises B144, B6, B31, B40, B44, B48, B71, B78, B81, B154, B194, B213, B224, B228, B281, and C10;

[0261]Bin 3 comprises B159, A201, B17, B26, B69, B130, B132, B142, B201, B236, B238, B248, B251, B280, and...

example 3

Deposits

Deposit of Cell Lines and DNA

[0277]The following hybridoma cell lines were deposited with the American Type Culture Collection (ATCC) located at 10801 University Boulevard, Manassas, Va. 20110-2209, U.S.A., and accorded accession numbers.

TABLE 2ATCC depositsHybridomaATCC Accession No.Deposit Date

[0278]The names of the deposited hybridoma cell lines above may be shortened for convenience of reference. E.g. A10.3 corresponds to LpPLA2.A10.3. These hybridomas correspond to the clones (with their full names) listed in Table 2. Subclones of hybridomas are listed which have the same characteristics and properties of parental clones. Reference to a parent clone or hybridoma producing an anti-Lp-PLA2 antibody, such as LpPLA2.A10 or LpPLA2.A2, includes all subclones such as those listed in Table 2 above.

[0279]These deposits were made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides isolated anti-Lp-PLA2 antibodies that bind to Lp-PLA2. The invention also encompasses compositions comprising an anti-Lp-PLA2 antibody. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Lp-PLA2 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Lp-PLA2 antibodies. The invention encompasses a method of producing the anti-Lp-PLA2 antibodies. Other aspects of the invention are a method of detecting an Lp-PLA2 in a subject.

Description

SEQUENCE LISTING[0001]The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jul. 12, 2013, is named 12248-701-200_SL.txt and is 21,605 bytes in size.FIELD OF THE INVENTION[0002]The present invention relates to anti-Lipoprotein-associated Phospholipase A2 (Lp-PLA2) antibody compositions and methods of detecting and treating Lp-PLA2 related diseases.INCORPORATION BY REFERENCE[0003]All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.BACKGROUND OF THE INVENTIONIntroduction[0004]Lipoprotein-associated Phospholipase A2 (Lp-PLA2) is an enzymatically active 50 kD protein that has been associated with Coronary vascular disease (CVD) including coronary h...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/40
CPCC07K16/40C07K2317/24C07K2317/56C07K2317/565C07K2317/76C12N9/20C12Y301/01047G01N33/573G01N2333/92
Inventor MILLER, PAUL LEVICORRAL, LAURA
Owner DIAZYME LAB INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com